Navigation Links
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Date:9/4/2007

evidence for the drug's activity as well as help inform dose selection for future studies."

ISIS 325568 Targets the Glucagon Receptor (GCGR)

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to improved glucose control and reduced levels of blood triglycerides without producing hypoglycemia. In addition, treatment with ISIS 325568 led to an increase in circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for diabetes and metabolic diseases, and the potential of the antise
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Arbor Pharmaceuticals, LLC. ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - ... of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and ... on the current therapeutic developmental pipeline of Arbor ... stages, therapeutics assessment by drug target, mechanism of ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Combination with CRESTOR (rosuvastatin calcium) Demonstrates Similar Lipid Effects ... ... Population, SAN FRANCISCO, June 7 ... type 2 diabetes,that were enrolled in a Phase III study showed ...
... the ADA,s Annual Scientific Sessions, SAN FRANCISCO, ... of the dose-finding study for its new,injectable diabetes ... American Diabetes Association,s (ADA) 68th Annual Scientific Sessions,meeting ... that AVE0010 was well tolerated and significantly,improved glycemic ...
Cached Medicine Technology:Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 2Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 3Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:10/1/2014)... Wi (PRWEB) October 01, 2014 UP4 ... of UP4 WOMEN’S probiotic to The National Network to ... of October. This organization was chosen through nationwide polling ... website and social media outlets. , “We are ... receive a portion of every sale of UP4 Women’s ...
(Date:10/1/2014)... This weekend Pope Francis drew world-wide attention to the problem ... seniors in St. Peter's Square in the Vatican, he decried ... the elderly is as inhuman as that against children," Pope ... discarded, victims of an abandonment that is tantamount to hidden ... is hurting our world so much," he said. , His ...
(Date:10/1/2014)... Los Angeles, CA (PRWEB) October 01, 2014 ... buyer power score of 3.1 out of 5, ... freezer users include food and beverage manufacturers, food ... manufacturers. As a result of these users' diversity, ... growth. As such, rising industrial production, consumer spending ...
(Date:10/1/2014)... 01, 2014 Nearly a year-and-a-half after ... County District Court jury awarded him $4.75 million; Michael ... years old. Casper had been too sick to ... According to the Court Documents (District Court, Pueblo County ... a benign non-cancerous condition of his prostate, when he ...
(Date:9/30/2014)... (HealthDay News) -- There,s no genetic evidence that high ... a new study says. Some previous research had ... people against type 2 diabetes, raising the possibility of ... sugar disease. In this study, British researchers investigated ... focusing on genes that control blood levels of vitamin ...
Breaking Medicine News(10 mins):Health News:UP4 Probiotics Partners with The National Network to End Domestic Violence 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 2Health News:Pope Francis Shines New Spotlight on Neglect of Elderly, Survey Finds Elder Self-Neglect is a Growing and Hidden Problem in U.S. says NAPGCM 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Industrial Freezers Procurement Category Market Research Report Now Available from IBISWorld 4Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2
... Mii amo, a destination spa,at Enchantment Resort, for ... the winter solstice on December 21. Activities include ... Native,American Program Director R.J. Joseph and special guest, ... Elder from the Blood Reserve,in Standoff, Alberta, Canada,s ...
... planned bequest comes at stem cell symposium, ANN ... retail pioneer A. Alfred Taubman announced a $22 million ... research institute aimed at,understanding, treating and preventing human disease., ... it again --,announcing that he will bequeath an additional ...
... a Man Wanted to Know But Was Afraid to ... 4.3 million babies born,in the U.S. each year but ... BEING DAD is a revealing, entertaining and inspirational DVD ... who,have recently gone through the pregnancy and delivery process. ...
... developed a magnetic resonance imaging (MRI)-based method for detecting and ... in patients who have undergone a procedure to treat atrial ... Oct. 7, 2008, issue of the Journal of the ... is an arrhythmia, or abnormal heart rhythm, that involves the ...
... (OTCBB:WYND), the ideas-to-revenues social media company, announced ... www.muveinc.com ), to create an interactive marketing ... corporate wellness program. Wyndstorm,s design project will ... use of wellness programs among employees via ...
... 7 The Catholic Health,Association of the United ... (CHI), Denver; Covenant Health Systems, Lexington, MA;,and Trinity ... effort to,raise awareness about global climate change., ... National Religious,Partnership for the Environment (NRPE) and the ...
Cached Medicine News:Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:Catholic Health Organizations Launch Ministry-Wide Effort to Raise Awareness About Global Climate Change 2
DNA/RNA preparation in 8-multi channels...
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... Bottled Water, The Simplicity personal water system ... currently use bottled water. In addition to ... store bottled water, your laboratory applications may ... be absorbed from containers and cause water ...
... of Type I ultrapure water, , Ultrapure ... System is designed to provide the "final ... by reverse osmosis, distillation or deionization. Super-Q ... which exceeds Type I ASTM/CAP/NCCLS specifications.,The Super-Q ...
Medicine Products: